GlassScriptPhysician profile
Hai S Park
NPI 1508805839
$5,931.41
in general payments reported to CMS, 2019-2025
41 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,067 · 2020: $673 · 2021: $835 · 2022: $923 · 2023: $742 · 2024: $968 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,087 · Education: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.49 |
| Education | $345.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $807.28 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $725.54 | 2019-2025 | Tagrisso, Lynparza |
| Alexion Pharmaceuticals, INC. | $571.93 | 2019-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $468.95 | 2019-2025 | |
| Janssen Biotech, INC. | $435.26 | 2022-2025 | Rybrevant, Erleada, Darzalex |
| Bayer Healthcare Pharmaceuticals INC. | $414.25 | 2019-2025 | |
| Incyte Corporation | $340.05 | 2019-2025 | Jakafi |
| Celgene Corporation | $318.48 | 2022-2024 | Reblozyl, Pomalyst |
| Amgen INC. | $237.02 | 2019-2023 | Lumakras, Nplate, Xgeva |
| Amarin Pharma, INC. | $225.18 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $154.87 | 2019-2023 | Keytruda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.60 | 2019-2023 | Gilotrif |
| Mallinckrodt Enterprises LLC | $145.91 | 2019 | |
| Novo Nordisk INC | $107.41 | 2021-2022 | |
| Lilly USA, LLC | $100.71 | 2019-2023 | Verzenio |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hai Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.